Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection
dc.contributor.author | Pinto, Melissa D. | |
dc.contributor.author | Lambert, Natalie | |
dc.contributor.author | Downs, Charles A. | |
dc.contributor.author | Abrahim, Heather | |
dc.contributor.author | Hughes, Thomas D. | |
dc.contributor.author | Rahmani, Amir M. | |
dc.contributor.author | Burton, Candace W. | |
dc.contributor.author | Chakraborty, Rana | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2022-07-26T16:05:30Z | |
dc.date.available | 2022-07-26T16:05:30Z | |
dc.date.issued | 2022-03-01 | |
dc.description.abstract | Postacute sequelae of SARS-CoV2 (PASC) infection is an emerging global health crisis, variably affecting millions worldwide. PASC has no established treatment. We describe 2 cases of PASC in response to opportune administration of over-the-counter antihistamines, with significant improvement in symptoms and ability to perform activities of daily living. Future studies are warranted to understand the potential role of histamine in the pathogenesis of PASC and explore the clinical benefits of antihistamines in the treatment of PASC. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Pinto, M. D., Lambert, N., Downs, C. A., Abrahim, H., Hughes, T. D., Rahmani, A. M., Burton, C. W., & Chakraborty, R. (2022). Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection. The Journal for Nurse Practitioners, 18(3), 335–338. https://doi.org/10.1016/j.nurpra.2021.12.016 | en_US |
dc.identifier.issn | 1555-4155 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/29643 | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.nurpra.2021.12.016 | en_US |
dc.relation.journal | The Journal for Nurse Practitioners | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Publisher | en_US |
dc.subject | antihistamine | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | long-COVID | en_US |
dc.title | Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Pinto2022Antihistamines-CCBYNCND.pdf
- Size:
- 1.15 MB
- Format:
- Adobe Portable Document Format
- Description:
- Article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: